Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia

Hypertension Research

Volumn 39, Issue 8, 2016, Pages 593-597

  Kohagura, Kentaro ^a,b   Tana, Takeshi ^c   Higa, Akira ^c   Yamazato, Masanobu ^b   Ishida, Akio ^b   Nagahama, Kazufumi ^b   Sakima, Atsushi ^b   Iseki, Kunitoshi ^d   Ohya, Yusuke ^a,b  

^a UNIVERSITY HOSPITAL OF THE RYUKYUS   (Japan)

^b Ryukyus Graduate School of Medicine ^*  (Japan)

^c Shuri Jokamachi Clinic   (Japan)

^d Tomishiro Central Hospital   (Japan)

Author keywords

chronic kidney disease; uric acid; xanthine oxidase inhibitor

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; URIC ACID; ENZYME INHIBITOR; XANTHINE OXIDASE;

ADULT; AGED; ARTICLE; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URIC ACID BLOOD LEVEL; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE; COMPLICATION; DRUG EFFECTS; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME;

AGED; ALLOPURINOL; BLOOD PRESSURE; ENZYME INHIBITORS; FEBUXOSTAT; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; HYPERURICEMIA; KIDNEY; MALE; MIDDLE AGED; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME; URIC ACID; XANTHINE OXIDASE;

EID: 84982830429     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2016.37     Document Type: Article

References (27)

1. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: A systematic review and meta-Analysis. Arthritis Care Res (Hoboken) 2011; 63: 102-110.
2. Nagahama K, Inoue T, Iseki K, Touma T, Kinjo K, Ohya Y, Takishita S. Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res 2004; 27: 835-841.
3. Nagahama K, Inoue T, Kohagura K, Kinjo K, Ohya Y. Associations between serum uric acid levels and the incidence of hypertension and metabolic syndrome: A 4-year follow-up study of a large screened cohort in Okinawa, Japan. Hypertens Res 2015; 38: 213-218.
4. Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 2001; 24: 691-697.
5. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004; 44: 642-650.
6. Johnson RJ, Nakagawa T, Jalal D, Sánchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant 2013; 28: 2221-2228.
7. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: A randomized trial. JAMA 2008; 300: 924-932.
8. Nagahama K, Iseki K, Inoue T, Touma T, Ikemiya Y, Takishita S. Hyperuricemia and cardiovascular risk factor clustering in a screened cohort in Okinawa, Japan. Hypertens Res 2004; 27: 227-233.
9. Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH, Grobbee DE, Shahinfar S, de Zeeuw D, Lambers Heerspink HJ. Effect of a reduction in uric acid on renal outcomes during losartan treatment: A post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension 2011; 58: 2-7.
10. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, Arroyo D, Luño J. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010; 5: 1388-1393.
11. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47: 51-59.
12. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode MJapan Atherosclerosis Society (JAS) Committee for Epidemiology and Clinical Management of Atherosclerosis. Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007; 14: 155-158.
13. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida ACollaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53: 982-992.
14. Bose B, Badve SV, Hiremath SS, Boudville N, Brown FG, Cass A, de Zoysa JR, Fassett RG, Faull R, Harris DC, Hawley CM, Kanellis J, Palmer SC, Perkovic V, Pascoe EM, Rangan GK, Walker RJ, Walters G, Johnson DW. Effects of uric acid-lowering therapy on renal outcomes: A systematic review and meta-Analysis. Nephrol Dial Transplant 2014; 29: 406-413.
15. Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension 2012; 60: 1148-1156.
16. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821.
17. Kohagura K, Kochi M, Miyagi T, Kinjyo T, Maehara Y, Nagahama K, Sakima A, Iseki K, Ohya Y. An association between uric acid levels and renal arteriolopathy in chronic kidney disease: A biopsy-based study. Hypertens Res 2013; 36: 43-49.
18. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002; 282: F991-F997.
19. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: An indicator of renal vascular involvement. Ann Intern Med 1980; 93: 817-821.
20. Kuwabara M, Niwa K, Nishi Y, Mizuno A, Asano T, Masuda K, Komatsu I, Yamazoe M, Takahashi O, Hisatome I. Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension. Hypertens Res 2014; 37: 785-789.
21. Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008; 19: 2407-2413.
22. De Nicola L, Minutolo R, Bellizzi V, Zoccali C, Cianciaruso B, Andreucci VE, Fuiano G, Conte GInvestigators of TArget Blood Pressure LEvels in Chronic Kidney Disease (TABLE in CKD) Study Group. Achievement of target blood pressure levels in chronic kidney disease: A salty question? Am J Kidney Dis 2004; 43: 782-795.
23. Agarwal R, Sinha AD, Pappas MK, Ammous F. Chlorthalidone for poorly controlled hypertension in chronic kidney disease: An interventional pilot study. Am J Nephrol 2014; 39: 171-182.
24. Lin CS, Lee WL, Hung YJ, Lee DY, Chen KF, Chi WC, Chang SC. Prevalence of hyperuricemia and its association with antihypertensive treatment in hypertensive patients in Taiwan. Int J Cardiol 2012; 156: 41-46.
25. Høieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Chen C, Dahlöf BLIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041-1049.
26. Shibagaki Y, Ohno I, Hosoya T, Kimura K. Safety, efficacy and renal effect of febuxostat in patients with moderate-To-severe kidney dysfunction. Hypertens Res 2014; 37: 919-925.
27. Goicoechea M, Garcia de Vinuesa S, Verdalles U, Verde E, Macias N, Santos A, Pérez de Jose A, Cedeño S, Linares T, Luño J. Allopurinol and progression of CKD and cardiovascular events: long-Term follow-up of a randomized clinical trial. Am J Kidney Dis 2015; 65: 543-549.